Assessment of p53 protein expression in normal mucose and benign and malignant lesions of the nasal cavity

Oncology

Volumn 55, Issue 2, 1998, Pages 168-173

  Fang, Sheen Yie ^a   Yan, Jin Jou ^a   Ohyama, Masuru ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Carcinoma; Inverted papilloma; Nasal mucosa; p53 protein

Indexed keywords

MUTAGENIC AGENT; PROTEIN P53;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVERTED PAPILLOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NOSE CAVITY CANCER; NOSE CAVITY TUMOR; NOSE MUCOSA; PAPILLOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; NOSE DISEASES; NOSE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0031962082     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011852     Document Type: Article

References (34)

1. Ogden GR, Kiddie RA, Lunny DP, Lane DP: Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992;166:389-394.
2. Lane DP: Cancer: p53, guardian of the genome. Nature 1992;358:15-16.
3. Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-899.
4. Xu L, Chen YT, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ, Garin-Chesa P: Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 1994;3:83-92.
5. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-326.
6. Gusterson BA, Anbazhagan R, Warren W, Midgely C, Lane DP, O'Hare M, Stamps A, Carter R, Jayatilake H: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991:6:1785-1789.
7. Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T: Biological characteristics of inverted papilloma of the urinary bladder. Br J Urol 1996;77:55-60.
8. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-935.
9. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
10. Field JK, Spandidos DA, Malliri A, Gosney JR, Yiagnisis M, Stell PM: Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 1991;64:573-577.
11. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
12. Hayes RB, Raatgever JW, de Bruyn A, Gerin M: Cancer of the nasal cavity and paranasal sinuses, and formaldehyde exposure. Int J Cancer 1986;37:487-492.
13. Macdonald MR, Le KT, Freeman J, Hui MF, Cheung RK, Dosch HM: A majority of inverted sinonasal papillomas carries Epstein-Barr virus genomes. Cancer 1995;75:2307-2312.
14. Bielamowicz S, Calcaterra TC, Watson D: Inverting papilloma of the head and neck: The UCLA update. Otolaryngol Head Neck Surg 1993;109:71-76.
15. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
16. Hyams VJ: Papillomas of the nasal cavity and paranasal sinuses: A clinicopathological study of 315 cases. Ann Otol Rhinol Laryngol 1971; 80:192-206.
17. Banks L, Matlashewski G, Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-534.
18. Cagle PT, Brown RW, Lebovitz ML: p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 1994;25:443-448.
19. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
20. Carder PJ, Cripps KJ, Morris R, Collins S, White S, Bird CC, Wyllie AH: Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 1995;71: 215-218.
21. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL: The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993;119:1118-1122.
22. Yan JJ, Tzeng CC, Jin YT: Overexpression of p53 protein in squamous cell carcinoma of buccal mucosa and tongue in Taiwan: An immunohistochemical and clinicopathological study. J Oral Pathol Med 1996;25:55-59.
23. Furuta Y, Shinohara T, Sano K, Nagashima K, Inoue K, Tanaka K, Inuyama Y: Molecular pathologic study of human papillomavirus infection in inverted papilloma and squamous cell carcinoma of the nasal cavities and paranasal sinuses. Laryngoscope 1991;101:79-85.
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136.
25. Scheffner M, Munger K, Byrne JC, Howley PM: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991;88:5523-5527.
26. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
27. Matlashewski G, Banks L, Pim D, Crawford L: Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 1986;154:665-672.
28. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-717.
29. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-4480.
30. Imbus HR, Dyson WL: A review of nasal cancer in furniture manufacturing and woodworking in North Carolina, the United States, and other countries. J Occup Med 1987;29:734-740.
31. Ng TP: A case-referent study of cancer of the nasal cavity and sinuses in Hong Kong. Int J Epidemiol 1986;15:171-175.
32. Gallo O, Chiarelli I, Bianchi S, Calzolari A, Simonetti L, Berardino P: Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Clin Cancer Res 1996;2:1577-1582.
33. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
34. Lavertu P, Roberts JK, Kraus DH, Levine HL, Wood BG, Medendorp SV, Tucker HM: Squamous cell carcinoma of the paranasal sinuses: The Cleveland clinic experience 1977-1986. Laryngoscope 1989;99:1130-1136.